F
Francesca Ricci
Researcher at Mario Negri Institute for Pharmacological Research
Publications - 166
Citations - 4322
Francesca Ricci is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Mesenchymal stem cell & Protein kinase B. The author has an hindex of 33, co-authored 166 publications receiving 3687 citations.
Papers
More filters
Journal ArticleDOI
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts
P. L. Tazzari,Alessandra Cappellini,Francesca Ricci,Camilla Evangelisti,Veronica Papa,Tiziana Grafone,Giovanni Martinelli,Roberto Conte,Lucio Cocco,James A. McCubrey,Alberto M. Martelli,Alberto M. Martelli +11 more
TL;DR: Evidence is presented that MRP1, but not P-gp, expression is under the control of the PI3K/Akt axis in AML blasts, and data suggest that PI3k/AKT activation may lead to the development of chemoresistance inAML blasts through a mechanism involving a p53-dependent suppression of MRP 1 expression.
Journal ArticleDOI
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells
Veronica Papa,P. L. Tazzari,Francesca Chiarini,Alessandra Cappellini,Francesca Ricci,Anna Maria Billi,Camilla Evangelisti,Emanuela Ottaviani,Giovanni Martinelli,Nicoletta Testoni,James A. McCubrey,Alberto M. Martelli +11 more
TL;DR: The findings indicate that perifosine, either alone or in combination with existing drugs, might be a promising therapeutic agent for the treatment of those AML cases characterized by upregulation of the PI3K–Akt survival pathway.
Journal ArticleDOI
Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition
Maria Rosaria Sapienza,Fabio Fuligni,Claudio Agostinelli,Claudio Tripodo,Simona Righi,Maria Antonella Laginestra,Alessandro Pileri,Manuela Mancini,Martina Rossi,Francesca Ricci,Anna Gazzola,Federica Melle,Claudia Mannu,Francesca Ulbar,Mario Arpinati,Marco Paulli,Takahiro Maeda,Davide Gibellini,Livio Pagano,Nicola Pimpinelli,Marco Santucci,Lorenzo Cerroni,Carlo M. Croce,Fabio Facchetti,Pier Paolo Piccaluga,Stefano Pileri +25 more
TL;DR: A molecular signature representative of the transcriptional abnormalities of BPDCN is identified and a cellular model proposing a novel therapeutic approach in the setting of this otherwise incurable disease is developed.
Journal ArticleDOI
Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations.
Francesca Ricci,Francesca Bizzaro,Marta Cesca,Federica Guffanti,Monica Ganzinelli,Alessandra Decio,Carmen Ghilardi,Patrizia Perego,Robert Fruscio,Alessandro Buda,Rodolfo Milani,Paola Ostano,Giovanna Chiorino,Maria Rosa Bani,Giovanna Damia,Raffaella Giavazzi +15 more
TL;DR: A panel of patient-derived EOC xenografts that recapitulate the recently type I and type II classification serves to study the biology of ovarian cancer, identify tumor-specific molecular markers, and develop novel treatment modalities.
Journal ArticleDOI
Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo
Laura Carrassa,Rosaria Chilà,Monica Lupi,Francesca Ricci,Cinzia Celenza,Marco Mazzoletti,Massimo Broggini,Giovanna Damia +7 more
TL;DR: In vivo treatment of mice bearing OVCAR-5 xenografts with the combination of Chk1 and Wee1 inhibitors led to greater tumor growth inhibition than with the inhibitors used as single agents with no toxicity, providing a strong rationale for the clinical investigation of the combined treatment.